沙利度胺加联合化疗治疗多发性骨髓瘤20例临床研究

目的评价沙利度胺（Thalidomide）加联合化疗（VAD方案和MP方案）治疗初发多发性骨髓瘤（MM）的疗效和不良反应。方法沙利度胺起始剂量为200 mg/d,每周递增100 mg,至患者不能耐受或最高剂量不超过400 mg/d。每间隔四周化疗一次,联合VAD方案（T-VAD组）或联合MP方案（T-MP组）。结果沙利度胺加联合化疗总有效率为75%,T-VAD组有效率83.3%,T-MP组有效率62.5%,两组差异无统计学意义;中位生存时间52个月;常见的不良反应为便秘、嗜睡、水肿、指端麻木等。结论沙利度胺加联合化疗方案治疗多发性骨髓瘤疗效较好,不良反应能耐受。

Thalidomide combined with chemotherapy in the treatment of multiple myeloma

Objective To evaluate the therapeutic efficacy and side effects of thalidomide combined with VAD and MP in the treatment of multiple myeloma. Methods The beginning dose of thalidomide was 200mg/d, increased 100mg every week till the intolerant dose or less than 400mg/d. Combined with VAD or MP group for four weeks a cycle. Results The overall response rate of the thalidomide combined with chemotherapy was 75%. The response rate was 83.3% in T- VAD group, 62.5% in T- MP group, and there was no statistically significance. The median overall survival was 52 months. The mainly side effects include constipation, somnolence, edema etc. Conclusion The thalidomide combined with chemotherapy regimen is effective in the treatment of multiple myelo- ma, with tolerable side effects.